|
|
|
|
Lancet study shows early breast cancer reduction
A large, independent phase III randomised study in women with early breast cancer has shown that adding capecitabine to a treatment regimen containing standard agents allows more women to live cancer-free for longer.This update outlines the pre-planned,...
|
|
|
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
Chan JA et al.In some reports, 5-fluorouracil has been associated with modest activity in patients with neuroendocrine tumors. Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates.
|
|
|
Cellular Histone Modification Patterns Predict Prognosis and Treatment Response in Resectable Pancreatic Adeno
Ananya Manuyakorn, Rebecca Paulus, James Farrell, Nicole A.Dawson, Sheila Tze, Gardenia Cheung-Lau, Oscar Joe Hines, Howard Reber, David B. Seligson, Steve Horvath, Siavash K. Kurdistani, Chandhan Guha, and David W. Dawson* From the Department of...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-040
Keryx Biopharmaceuticals, Inc.announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 ...
|
|
|
Keryx signs agreement with FDA for Phase III colorectal cancer trial
Keryx Biopharmaceuticals has reached agreement with the FDA regarding a special protocol assessment, or SPA, on the design of the Phase III trial for its PI3K/Akt pathway inhibitor, KRX-0401, in patients with refractory metastatic colorectal cancer.The SPA...
|
|
|
AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of P
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. ...
|
|
|
Current advances and research in the treatment of pancreatic cancer
In the third of four science articles on cancer treatments, Steve Williamson, Adam Todd, Roz J.Anderson and Paul W. Groundwater discuss current and novel treatments for pancreatic cancer, including one which is derived from a flower Pancreatic cancer is...
|
|
|
terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial o
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - terna Zentaris Inc. ...
|
|
|
AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosine
- Canadian biopharmaceutical company AEterna Zentaris Inc (TSE: AEZ) said yesterday that its US partner, Keryx Biopharmaceuticals (NASDAQ: KERX), has reached an agreement with the US Food and Drug Administration (FDA) regarding a Special Protocol Assessment ...
|
|
|
AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosine
- Canadian biopharmaceutical company AEterna Zentaris Inc (TSE: AEZ) said yesterday that its US partner, Keryx Biopharmaceuticals (NASDAQ: KERX), has reached an agreement with the US Food and Drug Administration (FDA) regarding a Special Protocol Assessment ...
|
|
|
Keryx signs agreement with FDA for Phase III colorectal cancer tr...
Company: Keryx Biopharmaceuticals, Inc.(KERX) Keryx Biopharmaceuticals has reached agreement with the FDA regarding a special protocol assessment, or SPA, on the design of the Phase III trial for its PI3K/Akt pathway inhibitor, KRX-0401, in patients with...
|
|
|
Keryx signs agreement with FDA for Phase III colorectal cancer tr...
Company: Keryx Biopharmaceuticals, Inc.(KERX) Keryx Biopharmaceuticals has reached agreement with the FDA regarding a special protocol assessment, or SPA, on the design of the Phase III trial for its PI3K/Akt pathway inhibitor, KRX-0401, in patients with...
|
|
|
Keryx signs agreement with FDA for Phase III colorectal cancer trial
Keryx Biopharmaceuticals has reached agreement with the FDA regarding a special protocol assessment, or SPA, on the design of the Phase III trial for its PI3K/Akt pathway inhibitor, KRX-0401, in patients with refractory metastatic colorectal cancer.The SPA...
|
|
|
Keryx Biopharmaceuticals Announces Protocol Assessment Agreement With FDA For Phase 3 Trial Of KRX-0401 (Perif
Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX...
|
|
|
?terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Pe
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUBEC CITY, Feb. 3 /PRwire-FirstCall/ - terna Zentaris Inc. (Nasdaq:...
|
|
|
terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Per
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUBEC CITY, Feb. 3 /CNW Telbec/ - terna Zentaris Inc. (Nasdaq: TSX:...
|
|
|
†terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Tria
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell QU‰BEC CITY, Feb. 3 About the Phase 3 Trial Design The Phase 3 X-PECT (Xeloda(R) + Perifosine Evaluation in Colorectal cancer...
|
|
|
terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in...
|
|
|
AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /CNW Telbec/ - AEterna Zentaris Inc. (Nasdaq:...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
NEW YORK, Feb.3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase...
|
|
|
AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ...
|
|
|
AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute PR Newswire NEW YORK, Feb. 3 NEW YORK, Feb. 3 /PRNewswire-FirstCall/ ...
|
|
|
f?terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell QUBEC CITY, Feb. 3 About the Phase 3 Trial Design The Phase 3 X-PECT (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment)...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-040
NEW YORK PHASE 3 TRIAL DESIGN: The Phase 3 X-PECT (Xeloda, + Perifosine Evaluation in Colorectal cancer Treatment) trial will be a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine + capecitabine (capecitabine is a...
|
